Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer.

Shin-Heng Chiou | Viviana I Risca | Gordon X Wang | Dian Yang | Barbara M Grüner | Arwa S Kathiria | Rosanna K Ma | Dedeepya Vaka | Pauline Chu | Margaret Kozak | Laura Castellini | Edward E Graves | Grace E Kim | Philippe Mourrain | Albert C Koong | Amato J Giaccia | Monte M Winslow
Cancer discovery | 2017

Pancreatic ductal adenocarcinoma (PDAC) is one of the most metastatic and deadly cancers. Despite the clinical significance of metastatic spread, our understanding of molecular mechanisms that drive PDAC metastatic ability remains limited. By generating a genetically engineered mouse model of human PDAC, we uncover a transient subpopulation of cancer cells with exceptionally high metastatic ability. Global gene expression profiling and functional analyses uncovered the transcription factor BLIMP1 as a driver of PDAC metastasis. The highly metastatic PDAC subpopulation is enriched for hypoxia-induced genes, and hypoxia-mediated induction of BLIMP1 contributes to the regulation of a subset of hypoxia-associated gene expression programs. These findings support a model in which upregulation of BLIMP1 links microenvironmental cues to a metastatic stem cell character.Significance: PDAC is an almost uniformly lethal cancer, largely due to its tendency for metastasis. We define a highly metastatic subpopulation of cancer cells, uncover a key transcriptional regulator of metastatic ability, and define hypoxia as an important factor within the tumor microenvironment that increases metastatic proclivity. Cancer Discov; 7(10); 1184-99. ©2017 AACR.See related commentary by Vakoc and Tuveson, p. 1067This article is highlighted in the In This Issue feature, p. 1047.

Pubmed ID: 28790031

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA198291
  • Agency: NCI NIH HHS, United States
    Id: P01 CA067166
  • Agency: NCI NIH HHS, United States
    Id: R01 CA197136
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH099647
  • Agency: NCI NIH HHS, United States
    Id: R00 CA151968
  • Agency: NCI NIH HHS, United States
    Id: P30 CA124435

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.